Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily rifapentine + isoniazid for 1 month vs daily rifampicin + isoniazid for 3 months in latent tuberculosis infection among asylum seekers and refugees
2019-002063-95Phase 3Terminated
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifapentine, isoniazid and rifampicin in latent tuberculosis infection (LTBI) (2 arms), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Treatment completion rate. Started May 2021; status: terminated.
02
Drugs
rifapentineisoniazidrifampicin
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2019-002063-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002063-95.